BusinessWorld Online covers new trial results for Lilly's retatrutide and what the drug could mean for patients going forward.
Recap by typeshit. Full story at BusinessWorld Online.
Half of people with diabetes for 10 years or more said they were very satisfied on a GLP-1. Gen Z users were the most likely to stop and restart treatment.
64% of current users faced some negative reaction. Men, BIPOC respondents and the newly diagnosed reported it most, while 69% of boomers felt none.
The workflow uses glutathione or sulfatase triggers to target organelles and tumors in mice, and the authors say it takes 92 to 115 days to run.
A University of Pennsylvania mouse study found on-off GLP-1 use left mice 20 per cent heavier than those kept on the drug, and doctors warn human effects are unknown.
Lynette Ntuli posts about a risk she says doctors flag for type 2 diabetics taking Ozempic. The text is cut off, so see her full post for details.
50:19
The two surgeons sit down to discuss what's happening in cosmetic surgery, how GLP-1 drugs fit in, and longevity.
Loading…